Incremental Prognostic Significance of the Elevated Levels of Pentraxin 3 in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction
Open Access
- 15 August 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 3 (4)
- https://doi.org/10.1161/jaha.114.000928
Abstract
Background: Pentraxin 3 ( PTX 3) is a novel inflammatory marker produced by various cell types including those of the vasculature and the heart. The relationship between inflammatory markers and prognosis of patients with heart failure with normal ejection fraction ( HFNEF ) remains unknown. We investigated whether plasma PTX 3 levels can predict future cardiovascular events in patients with HFNEF . Methods and Results: Plasma PTX3, high‐sensitivity C‐reactive protein, and B‐type natriuretic peptide levels were measured prospectively in 360 stable patients with HFNEF. The subsequent incidence of cardiovascular events, including cardiovascular death, nonfatal myocardial infarction (MI), unstable angina pectoris, nonfatal ischemic stroke, hospitalization for heart failure decompensation, and coronary revascularization, was determined. During a mean 30‐month follow‐up, 106 patients experienced cardiovascular events. These events were more frequent in patients with high plasma PTX3 levels (>3.0 ng/ mL ) than low levels (≤3.0 ng/ mL ). Multivariable Cox hazard analysis showed that PTX3 (hazard ratio: 1.16; 95% CI: 1.05 to 1.27; P P P <0.01). The C‐statistics for cardiovascular events substantially increased from 0.617 to 0.683 when PTX3 was added to the 5 previously identified prognostic factors. Conclusions: High plasma PTX 3 levels, but not other inflammatory markers, are correlated with future cardiovascular events in patients with HFNEF . PTX 3 may be a useful biomarker for assessment of risk stratification in HFNEF . Clinical Trial Registration: URL : http://www.umin.ac.jp ; Unique identifier: UMIN 000002170.Keywords
This publication has 46 references indexed in Scilit:
- Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection FractionPLOS ONE, 2013
- Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trialsEuropean Journal of Heart Failure, 2012
- Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionCirculation: Heart Failure, 2011
- Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2009
- Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial InfarctionCirculation, 2008
- C‐reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul StudyEuropean Journal of Heart Failure, 2008
- High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failureEuropean Heart Journal, 2005
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004